Close
Back to mobile site

Aileron Therapeutics (ALRN) Announces Clinical Trial Collaboration with Pfizer (PFE) to Evaluate ALRN-6924 in Combination with IBRANCE (palbociclib) in MDM2-Amplified Cancers

November 27, 2018 8:05 AM EST Send to a Friend
Aileron Therapeutics (NASDAQ: ALRN) today announced that it has entered into a clinical trial collaboration with Pfizer to evaluate the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login